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INTRODUCTION METHODS 
RESULTS 
CONCLUSIONS 
We genotyped (by PCR-RFLP) 110 SCA patients for the SNP 
rs11886868 located in intron 2 of the BCL11A gene (2p16.1). Also, 79 
SCA patients were screened for two other SNPs located in the HBS1L-
MYB intergenic region on chromosome 6 (rs4895441 and 
rs6929404).  
A normality test (K-S test) was applied to our sample and a normal 
statistical distribution of our dependent variable (%HbF) was not 
excluded. Therefore, we performed  an ANOVA to access whether 
there were differences in %HbF distribution among the possible 
genotypes of all SNPs. Multiple comparisons were performed with 
the Bonferroni test. 
Patients were also divided in two groups, one with HbF<8% and 
other with HbF 8%, and genotypic and allelic frequencies were 
compared between both using the Chi-square test of independence. 
All statistical analysis were performed with SPSS v17 statistical 
software. 
• We observed, in this group of SCA patients, a strong association of SNP rs11886868 in BCL11A gene with higher levels of HbF 
(α2γ2).  
BCL11A factor functions as a repressor of γ-globin genes expression, in cooperation with other co-factors[7] (Fig.2). The SNP 
rs11886868 probably impairs normal BCL11A gene expression, decreasing its ability to silence γ-globin genes, which leads to 
increased HbF levels in the adult life. 
 
• MYB factor is also thought to be a potent negative regulator of HbF expression (Fig. 2). However, we didn’t observe association of 
SNPs rs4895441 and rs6929404 located within the HBS1L-MYB intergenic region with the level of HbF.  
 
• The results gathered in this study confirm that genetic polymorphisms in some trans-acting factor genes can modulate the HbF 
level in SCA, with consequences in its pathophysiology. This knowledge may provide new insights for the development of new 
therapeutic strategies for this pathology. 
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BCL11A (rs11886868) 
[110  SCA patients] 
Low HbF (<8,0%) 
[55 patients] 
High HbF (≥8,0 %) 
[55 patients] 
Mean Median Max. Min. Mean Median Max. Min. 
4,6 4,7 7,7 1,5 12,3 11,0 22,5 8,0 
rs4895441 N Mean HbF (%) Median HbF (%) p value* 
A/A 72 8,8 8,2 
0.3061 A/G 7 6,8 6,7 
G/G 0 - - 
rs6929404 N Mean HbF (%) Median HbF (%) p value* 
A/A 11 8,9 7,5 
0.9643 
 A/C 38 8,7 8,1 
C/C 30 8,5 8,0 
* Statistical significance considered at p<0.05. 
1 T Test; 2 ANOVA analysis 
1. No association was found between genotypes and HbF level distribuition. 
rs11886868 N Mean HbF (%) Median HbF (%) p value* 
T/T 51 6,1 5,8 
<0.0011 T/C 50 9,4 9,3 
C/C 9 16,5 15,0 
* Statistical significance considered at p<0.05. 
1 ANOVA analysis. rs11886868 Low HbF (<8%) High HbF (≥8%) p value* 
Genotypic frequencies 
TT 35 16 
<0.0011 TC 20 30 
CC 0 9 
Allelic frequencies 
T 90 62 
<0.0011 
C 20 48 
1. We found statistical significant differences between the three genotypes of SNP rs11886868 
regarding %HbF distribution. This result reveals a strong association of this SNP with HbF levels. 
2. The reciprocal analysis further confirms this result (genotypic and allelic frequencies 
are differentially distributed between the low and high HbF groups). 
3. After multiple comparison analysis we were able to determine that the genotypes 
with at least one C allele were strongly associated with higher HbF percentages.  
* Statistical significance considered at p<0.05. 
1 Chi-Square test of independance 
Genotypes Mean difference (HbF %) p value* 
T/T C/T -3,3 <0.0011 
T/T C/C -10,4 <0.0011 
C/T C/C -7,1 <0.0011 
* Statistical significance considered at p<0.05. 
1 Bonferroni Test 
BCL11A – SNP rs11886868 
HBS1L-MYB – SNPs rs4895441 and rs6929404 
Sickle Cell Anemia (SCA), one of the most common autosomal recessive hereditary 
anemia, is caused by a mutation in the β-globin gene (HBB:c.20A>T) on 11p15.5. This 
originates a hemoglobin variant named HbS, as opposed to the normal adult HbA. HbS 
ability to polymerize when deoxygenated gives rise to abnormal sickled red blood cells  
(Fig.1).  
 
The two major SCA manifestations are chronic hemolysis and recurrent vaso-occlusive 
episodes[1]. However, the clinical phenotype of SCA is heterogeneous, ranging from 
relatively mild to severe due to the modifying effect of both environmental and 
genetic factors[2, 3].  
The level of fetal hemoglobin (HbF) is a known modifier of the disease severity[reviewed in 4] and its variability among 
SCA patients has been associated with polymorphisms in both globinic cis-acting elements (e.g. the XmnI SNP, 
upstream HBG2)[5, 6] and in non-globinic trans-acting factors  (e.g. BCL11A and HBS1L-MYB intergenic region)[5].  
In this study, we aimed to contribute to a better understanding of the non-globinic genetic factors modulating the 
expression level of  HbF in SCA. 
Fig. 2. Schematic representation of BCL11A/MYB  mediated 
silencing of γ-globin genes. Adapted from Xu J el al. (2010) [7]. 
Fig. 1. Normal red blood 
cells and a sickled  one.  
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